Last reviewed · How we verify

Pregabalin 50mg

Hospital for Special Surgery, New York · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Pregabalin 50mg is a Small molecule drug developed by Hospital for Special Surgery, New York. It is currently FDA-approved. Also known as: Lyrica.

Pregabalin 50mg is a small molecule that modulates voltage-gated calcium channels. It has been studied as a potential treatment for pain, particularly in trauma patients, to reduce opioid usage.

At a glance

Generic namePregabalin 50mg
Also known asLyrica
SponsorHospital for Special Surgery, New York
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pregabalin 50mg

What is Pregabalin 50mg?

Pregabalin 50mg is a Small molecule drug developed by Hospital for Special Surgery, New York.

Who makes Pregabalin 50mg?

Pregabalin 50mg is developed and marketed by Hospital for Special Surgery, New York (see full Hospital for Special Surgery, New York pipeline at /company/hospital-for-special-surgery-new-york).

Is Pregabalin 50mg also known as anything else?

Pregabalin 50mg is also known as Lyrica.

What development phase is Pregabalin 50mg in?

Pregabalin 50mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing